Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and Aging In Vivo

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Posimo, Jessica M ^a   Titler, Amanda M ^a   Choi, Hailey J H ^a   Unnithan, Ajay S ^a   Leak, Rehana K ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CATALASE; CERULOPLASMIN; GLUTATHIONE; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; HYDROGEN PEROXIDE; MICROTUBULE ASSOCIATED PROTEIN 2; PROTEASOME; UBIQUITIN;

AGING; ALLOCORTEX; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BRAIN FUNCTION; BRAIN LEVEL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NEOCORTEX; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; AUTOPHAGY; CELL AGING; CELL SURVIVAL; CEREBRAL CORTEX; FEMALE; GLUTATHIONE; HYDROGEN PEROXIDE; LEUPEPTINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOCORTEX; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; STRESS, PHYSIOLOGICAL; UBIQUITIN;

EID: 84874902170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058596     Document Type: Article

References (168)

1. Xilouri M, Stefanis L, (2010) Autophagy in the central nervous system: implications for neurodegenerative disorders. CNS & neurological disorders drug targets 9: 701-719.
2. Angot E, Steiner JA, Hansen C, Li JY, Brundin P, (2010) Are synucleinopathies prion-like disorders? Lancet neurology 9: 1128-1138.
3. Jellinger KA, (2009) Recent advances in our understanding of neurodegeneration. Journal of neural transmission 116: 1111-1162.
4. Dickson DW, (2009) Neuropathology of non-Alzheimer degenerative disorders. International journal of clinical and experimental pathology 3: 1-23.
5. Uversky VN, (2009) Intrinsic disorder in proteins associated with neurodegenerative diseases. Frontiers in bioscience: a journal and virtual library 14: 5188-5238.
6. Menzies FM, Ravikumar B, Rubinsztein DC, (2006) Protective roles for induction of autophagy in multiple proteinopathies. Autophagy 2: 224-225.
7. Walker LC, Levine H, 3rd, Mattson MP, Jucker M (2006) Inducible proteopathies. Trends in neurosciences 29: 438-443.
8. Walker LC, LeVine H, (2000) The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Molecular neurobiology 21: 83-95.
9. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
10. Braak H, Braak E, Bohl J, (1993) Staging of Alzheimer-related cortical destruction. Eur Neurol 33: 403-408.
11. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16: 271-278; discussion 278-284.
12. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, et al. (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249Suppl 3: III/1-5.
13. Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, et al. (2010) Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Movement disorders: official journal of the Movement Disorder Society 25: 2508-2515.
14. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y, (2010) Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 25Suppl 1: S78-82.
15. Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, et al. (2010) Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov Disord 25: 2508-2515.
16. Jellinger KA (2011) Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci.
17. Braak H, Rub U, Gai WP, Del Tredici K, (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517-536.
18. Braak H, Rub U, Schultz C, Del Tredici K, (2006) Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 9: 35-44.
19. Stranahan AM, Mattson MP, (2010) Selective Vulnerability of Neurons in Layer II of the Entorhinal Cortex during Aging and Alzheimer's Disease. Neural Plast 2010: 108190.
20. Duyckaerts C, Delatour B, Potier MC, (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118: 5-36.
21. Chu CC, Tranel D, Damasio AR, Van Hoesen GW, (1997) The autonomic-related cortex: pathology in Alzheimer's disease. Cereb Cortex 7: 86-95.
22. Braak H, Del Tredici K, Bohl J, Bratzke H, Braak E, (2000) Pathological changes in the parahippocampal region in select non-Alzheimer's dementias. Ann N Y Acad Sci 911: 221-239.
23. Brun A, Englund E, (1981) Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 5: 549-564.
24. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, et al. (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98: 10966-10971.
25. Nestor PJ, Fryer TD, Smielewski P, Hodges JR, (2003) Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 54: 343-351.
26. Brun A, Englund E, (1986) Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods. Prog Neuropsychopharmacol Biol Psychiatry 10: 297-308.
27. Bradley KM, O'Sullivan VT, Soper ND, Nagy Z, King EM, et al. (2002) Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 125: 1772-1781.
28. Bancher C, Braak H, Fischer P, Jellinger KA, (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett 162: 179-182.
29. Albert MS, (1996) Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci U S A 93: 13547-13551.
30. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, et al. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41: 17-24.
31. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, et al. (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16: 4491-4500.
32. Thal DR, Rub U, Orantes M, Braak H, (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800.
33. Thal DR, Del Tredici K, Braak H, (2004) Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004: pe26.
34. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, et al. (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63: 204-212.
35. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, et al. (2008) MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71: 743-749.
36. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT, (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42: 631-639.
37. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, et al. (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62: 925-931.
38. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, et al. (2001) Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 56: 730-736.
39. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA, (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64: 1404-1410.
40. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM (2011) Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry.
41. Kalaitzakis ME, Pearce RK, (2009) The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol 118: 587-598.
42. Jellinger KA, (2006) The morphological basis of mental dysfunction in Parkinson's disease. Journal of the neurological sciences 248: 167-172.
43. Mattila PM, Roytta M, Torikka H, Dickson DW, Rinne JO, (1998) Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol 95: 576-582.
44. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, et al. (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54: 1916-1921.
45. Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, et al. (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 106: 83-88.
46. Braak H, Rub U, Del Tredici K, (2006) Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 248: 255-258.
47. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M, (2000) Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 100: 285-290.
48. Double KL, Halliday GM, McRitchie DA, Reid WG, Hely MA, et al. (1996) Regional brain atrophy in idiopathic parkinson's disease and diffuse Lewy body disease. Dementia 7: 304-313.
49. Ibarretxe-Bilbao N, Junque C, Marti MJ, Tolosa E, (2011) Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease. J Neurol Sci 310: 70-74.
50. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO, (2004) Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 75: 1467-1469.
51. Riekkinen P Jr, Kejonen K, Laakso MP, Soininen H, Partanen K, et al. (1998) Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson's disease patients. Neuroreport 9: 1507-1511.
52. Lim SY, Fox SH, Lang AE, (2009) Overview of the extranigral aspects of Parkinson disease. Arch Neurol 66: 167-172.
53. Mattson MP, Kater SB, (1989) Development and selective neurodegeneration in cell cultures from different hippocampal regions. Brain Res 490: 110-125.
54. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O, (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 326: 155-158.
55. McNaught KS, Jenner P, (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 297: 191-194.
56. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW, (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179: 38-46.
57. Keller JN, Hanni KB, Markesbery WR, (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-439.
58. Lopez Salon M, Morelli L, Castano EM, Soto EF, Pasquini JM, (2000) Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 62: 302-310.
59. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, et al. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355.
60. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, et al. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69: 1326-1329.
61. Floor E, Wetzel MG, (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70: 268-275.
62. Jenner P, (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13Suppl 1: 24-34.
63. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, et al. (1986) Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2: 639-640.
64. Selley ML, (1998) (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med 25: 169-174.
65. Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, et al. (2009) Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's disease: JAD 17: 143-149.
66. Zeevalk GD, Razmpour R, Bernard LP, (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 62: 236-249.
67. Sofic E, Lange KW, Jellinger K, Riederer P, (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128-130.
68. Martin HL, Teismann P, (2009) Glutathione-a review on its role and significance in Parkinson's disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 23: 3263-3272.
69. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, et al. (2006) Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxidants & redox signaling 8: 1975-1986.
70. Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, et al. (2008) Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. Journal of Alzheimer's disease: JAD 15: 117-128.
71. Adair JC, Knoefel JE, Morgan N, (2001) Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57: 1515-1517.
72. Clark J, Clore EL, Zheng K, Adame A, Masliah E, et al. (2010) Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One 5: e12333.
73. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, et al. (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neuroscience letters 60: 109-114.
74. Sharma A, Kaur P, Kumar V, Gill KD, (2007) Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine. Cellular and molecular biology 53: 48-55.
75. Tucker S, Ahl M, Cho HH, Bandyopadhyay S, Cuny GD, et al. (2006) RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Current Alzheimer research 3: 221-227.
76. Pocernich CB, La Fontaine M, Butterfield DA, (2000) In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochemistry international 36: 185-191.
77. Fu AL, Dong ZH, Sun MJ, (2006) Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res Brain Res Protoc 1109: 201-206.
78. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, et al. (2003) The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Journal of neurochemistry 84: 1173-1183.
79. Martinez Banaclocha M, (2000) N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease. Brain Res Brain Res Protoc 859: 173-175.
80. Keller JN, Hanni KB, Markesbery WR, (2000) Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech Ageing Dev 113: 61-70.
81. Dasuri K, Zhang L, Ebenezer P, Liu Y, Fernandez-Kim SO, et al. (2009) Aging and dietary restriction alter proteasome biogenesis and composition in the brain and liver. Mech Ageing Dev 130: 777-783.
82. Keller JN, Gee J, Ding Q, (2002) The proteasome in brain aging. Ageing research reviews 1: 279-293.
83. Harman D, (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298-300.
84. Leak RK, Castro SL, Jaumotte JD, Smith AD, Zigmond MJ, (2010) Assaying multiple biochemical variables from the same tissue sample. J Neurosci Methods 191: 234-238.
85. Wang C, Sadovova N, Hotchkiss C, Fu X, Scallet AC, et al. (2006) Blockade of N-methyl-D-aspartate receptors by ketamine produces loss of postnatal day 3 monkey frontal cortical neurons in culture. Toxicological sciences: an official journal of the Society of Toxicology 91: 192-201.
86. Olivieri S, Conti A, Iannaccone S, Cannistraci CV, Campanella A, et al. (2011) Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. The Journal of neuroscience: the official journal of the Society for Neuroscience 31: 18568-18577.
87. Bayer SA, Altman J (1991) Neocortical Development: Raven Press.
88. Miller FD, Gauthier AS, (2007) Timing is everything: making neurons versus glia in the developing cortex. Neuron 54: 357-369.
89. Halliday GM, Stevens CH, (2011) Glia: Initiators and progressors of pathology in Parkinson's disease. Mov Disord 26: 6-17.
90. Gotz M (2001) Cerebral Cortex Development. Encyclopedia of Life Sciences: 1-7.
91. Mullett SJ, Hinkle DA, (2011) DJ-1 deficiency in astrocytes selectively enhances mitochondrial Complex I inhibitor-induced neurotoxicity. Journal of neurochemistry 117: 375-387.
92. Calabrese EJ, (2010) Hormesis is central to toxicology, pharmacology and risk assessment. Human & experimental toxicology 29: 249-261.
93. Giordano J, Ives JA, Jonas WB, (2008) Hormetic responses in neural systems: consideration, contexts, and caveats. Critical reviews in toxicology 38: 623-627.
94. Mattson MP, (2008) Hormesis defined. Ageing research reviews 7: 1-7.
95. Braak H, Del Tredici K, Schultz C, Braak E, (2000) Vulnerability of select neuronal types to Alzheimer's disease. Ann N Y Acad Sci 924: 53-61.
96. Kang R, Zeh HJ, Lotze MT, Tang D, (2011) The Beclin 1 network regulates autophagy and apoptosis. Cell death and differentiation 18: 571-580.
97. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, et al. (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402: 672-676.
98. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. The EMBO journal 19: 5720-5728.
99. Mizushima N, Yoshimori T, (2007) How to interpret LC3 immunoblotting. Autophagy 3: 542-545.
100. Iwata A, Riley BE, Johnston JA, Kopito RR, (2005) HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280: 40282-40292.
101. Janen SB, Chaachouay H, Richter-Landsberg C, (2010) Autophagy is activated by proteasomal inhibition and involved in aggresome clearance in cultured astrocytes. Glia 58: 1766-1774.
102. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, et al. (2007) Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. The American journal of pathology 171: 513-524.
103. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ, (2007) Potential therapeutic applications of autophagy. Nature reviews Drug discovery 6: 304-312.
104. Fuertes G, Martin De Llano JJ, Villarroya A, Rivett AJ, Knecht E, (2003) Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. The Biochemical journal 375: 75-86.
105. Klionsky DJ, Cuervo AM, Seglen PO, (2007) Methods for monitoring autophagy from yeast to human. Autophagy 3: 181-206.
106. Kaushik S, Cuervo AM, (2009) Methods to monitor chaperone-mediated autophagy. Methods Enzymol 452: 297-324.
107. Finn PF, Mesires NT, Vine M, Dice JF, (2005) Effects of small molecules on chaperone-mediated autophagy. Autophagy 1: 141-145.
108. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, et al. (2010) Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. The Journal of biological chemistry 285: 10850-10861.
109. Glickman MH, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428.
110. Pickart CM, (2004) Back to the future with ubiquitin. Cell 116: 181-190.
111. Lecker SH, Goldberg AL, Mitch WE, (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. Journal of the American Society of Nephrology: JASN 17: 1807-1819.
112. Voges D, Zwickl P, Baumeister W, (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068.
113. Pickering AM, Koop AL, Teoh CY, Ermak G, Grune T, et al. (2010) The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes. The Biochemical journal 432: 585-594.
114. Shang F, Taylor A, (2011) Ubiquitin-proteasome pathway and cellular responses to oxidative stress. Free radical biology & medicine 51: 5-16.
115. Besche HC, Peth A, Goldberg AL, (2009) Getting to first base in proteasome assembly. Cell 138: 25-28.
116. Aridon P, Geraci F, Turturici G, D'Amelio M, Savettieri G, et al. (2011) Protective role of heat shock proteins in Parkinson's disease. Neuro-degenerative diseases 8: 155-168.
117. Witt SN, (2010) Hsp70 molecular chaperones and Parkinson's disease. Biopolymers 93: 218-228.
118. Nagai Y, Fujikake N, Popiel HA, Wada K, (2010) Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Current pharmaceutical biotechnology 11: 188-197.
119. Koren J, 3rd, Jinwal UK, Lee DC, Jones JR, Shults CL, et al (2009) Chaperone signalling complexes in Alzheimer's disease. Journal of cellular and molecular medicine 13: 619-630.
120. Silver JT, Noble EG, (2012) Regulation of survival gene hsp70. Cell Stress Chaperones 17: 1-9.
121. Grochot-Przeczek A, Dulak J, Jozkowicz A, (2012) Haem oxygenase-1: non-canonical roles in physiology and pathology. Clinical science 122: 93-103.
122. Wu ML, Ho YC, Yet SF, (2011) A central role of heme oxygenase-1 in cardiovascular protection. Antioxidants & redox signaling 15: 1835-1846.
123. Aztatzi-Santillan E, Nares-Lopez FE, Marquez-Valadez B, Aguilera P, Chanez-Cardenas ME, (2010) The protective role of heme oxygenase-1 in cerebral ischemia. Central nervous system agents in medicinal chemistry 10: 310-316.
124. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D, (2009) Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. Journal of neurochemistry 110: 469-485.
125. Schipper HM, (2000) Heme oxygenase-1: role in brain aging and neurodegeneration. Exp Gerontol 35: 821-830.
126. Ding Q, Dimayuga E, Keller JN, (2006) Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxidants & redox signaling 8: 163-172.
127. Ling YH, Liebes L, Zou Y, Perez-Soler R, (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. The Journal of biological chemistry 278: 33714-33723.
128. Emanuele S, Calvaruso G, Lauricella M, Giuliano M, Bellavia G, et al. (2002) Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3. International journal of oncology 21: 857-865.
129. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, et al. (1999) Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 27: 544-553.
130. Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LM, et al. (2011) Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's disease: JAD 26: 59-68.
131. Fahn S, Cohen G, (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of neurology 32: 804-812.
132. Venkateshappa C, Harish G, Mahadevan A, Srinivas Bharath MM, Shankar SK (2012) Elevated Oxidative Stress and Decreased Antioxidant Function in the Human Hippocampus and Frontal Cortex with Increasing Age: Implications for Neurodegeneration in Alzheimer's Disease. Neurochemical research.
133. Dreger H, Westphal K, Weller A, Baumann G, Stangl V, et al. (2009) Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovascular research 83: 354-361.
134. Alexandrova A, Petrov L, Georgieva A, Kirkova M, Kukan M, (2008) Effects of proteasome inhibitor, MG132, on proteasome activity and oxidative status of rat liver. Cell biochemistry and function 26: 392-398.
135. Leak RK, Zigmond MJ, Liou AK, (2008) Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism. J Neurochem 106: 860-874.
136. Kaneko K, Hineno A, Yoshida K, Ikeda S, (2008) Increased vulnerability to rotenone-induced neurotoxicity in ceruloplasmin-deficient mice. Neurosci Lett 446: 56-58.
137. Hineno A, Kaneko K, Yoshida K, Ikeda S, (2011) Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity. Neurochemical research 36: 2127-2135.
138. Texel SJ, Zhang J, Camandola S, Unger EL, Taub DD, et al. (2011) Ceruloplasmin deficiency reduces levels of iron and BDNF in the cortex and striatum of young mice and increases their vulnerability to stroke. PLoS One 6: e25077.
139. Loeffler DA, Sima AA, LeWitt PA, (2001) Ceruloplasmin immunoreactivity in neurodegenerative disorders. Free Radic Res 35: 111-118.
140. Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, et al. (1996) Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res Brain Res Protoc 738: 265-274.
141. Mezzetti A, Lapenna D, Romano F, Costantini F, Pierdomenico SD, et al. (1996) Systemic oxidative stress and its relationship with age and illness.Associazione Medica "Sabin". Journal of the American Geriatrics Society 44: 823-827.
142. Mezzetti A, Pierdomenico SD, Costantini F, Romano F, De Cesare D, et al. (1998) Copper/zinc ratio and systemic oxidant load: effect of aging and aging-related degenerative diseases. Free radical biology & medicine 25: 676-681.
143. Memisogullari R, Bakan E, (2004) Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. Journal of diabetes and its complications 18: 193-197.
144. Chacko SK, Cheluvappa R, (2010) Increased ceruloplasmin and fibrinogen in type 2 diabetes corresponds to decreased anti-oxidant activity in a preliminary tertiary South Indian hospital study. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 118: 64-67.
145. Taysi S, Polat F, Gul M, Sari RA, Bakan E, (2002) Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatology international 21: 200-204.
146. Louro MO, Cocho JA, Mera A, Tutor JC, (2000) Immunochemical and enzymatic study of ceruloplasmin in rheumatoid arthritis. Journal of trace elements in medicine and biology: organ of the Society for Minerals and Trace Elements 14: 174-178.
147. Unnithan AS, Choi HJ, Titler AM, Posimo JM, Leak RK, (2012) Rescue from a two hit, high-throughput model of neurodegeneration with N-acetyl cysteine. Neurochemistry international 61: 356-368.
148. Pastore A, Federici G, Bertini E, Piemonte F, (2003) Analysis of glutathione: implication in redox and detoxification. Clinica chimica acta; international journal of clinical chemistry 333: 19-39.
149. Shen D, Dalton TP, Nebert DW, Shertzer HG, (2005) Glutathione redox state regulates mitochondrial reactive oxygen production. The Journal of biological chemistry 280: 25305-25312.
150. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, et al. (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64: 816-830.
151. Nedelsky NB, Todd PK, Taylor JP, (2008) Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochimica et biophysica acta 1782: 691-699.
152. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, et al. (2006) Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 66: 3754-3763.
153. Dringen R, (2000) Metabolism and functions of glutathione in brain. Progress in neurobiology 62: 649-671.
154. Pocernich CB, Butterfield DA (2011) Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochimica et biophysica acta.
155. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF, (2003) The changing faces of glutathione, a cellular protagonist. Biochemical pharmacology 66: 1499-1503.
156. Jin L, Wang J, Zhao L, Jin H, Fei G, et al. (2011) Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 134: 50-58.
157. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, et al. (2004) Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63: 1912-1917.
158. Lirong J, Jianjun J, Hua Z, Guoqiang F, Yuhao Z, et al. (2009) Hypoceruloplasminemia-related movement disorder without Kayser-Fleischer rings is different from Wilson disease and not involved in ATP7B mutation. Eur J Neurol 16: 1130-1137.
159. Shang HF, Jiang XF, Burgunder JM, Chen Q, Zhou D, (2006) Novel mutation in the ceruloplasmin gene causing a cognitive and movement disorder with diabetes mellitus. Mov Disord 21: 2217-2220.
160. Hochstrasser H, Tomiuk J, Walter U, Behnke S, Spiegel J, et al. (2005) Functional relevance of ceruloplasmin mutations in Parkinson's disease. Faseb J 19: 1851-1853.
161. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C, (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33: 1717-1723.
162. Torsdottir G, Kristinsson J, Snaedal J, Sveinbjornsdottir S, Gudmundsson G, et al. (2010) Case-control studies on ceruloplasmin and superoxide dismutase (SOD1) in neurodegenerative diseases: a short review. J Neurol Sci 299: 51-54.
163. Bharucha KJ, Friedman JK, Vincent AS, Ross ED, (2008) Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol 255: 1957-1962.
164. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, et al. (2008) Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals: an international journal on the role of metal ions in biology, biochemistry, and medicine 21: 367-372.
165. Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, et al. (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. Journal of neural transmission 113: 1763-1769.
166. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, et al. (2010) Copper and ceruloplasmin abnormalities in Alzheimer's disease. American journal of Alzheimer's disease and other dementias 25: 490-497.
167. Squitti R, Quattrocchi CC, Salustri C, Rossini PM, (2008) Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion 2: 23-27.
168. Chang YZ, Qian ZM, Wang K, Zhu L, Yang XD, et al. (2005) Effects of development and iron status on ceruloplasmin expression in rat brain. J Cell Physiol 204: 623-631.